dr. eyre on btk inhibitors in combination with venetoclax for mcl
Published 6 years ago • 169 plays • Length 1:52Download video MP4
Download video MP3
Similar videos
-
1:10
dr. eyre on resistance to btk inhibition in mcl
-
1:09
dr. goy discusses ibrutinib with venetoclax in mcl
-
1:56
dr. rule on the role of btk inhibitors in mcl
-
0:56
dr. eyre on results of venetoclax in relapsed/refractory mcl
-
3:27
venetoclax: an unmet need in r/r mantle cell lymphoma after btk inhibitors
-
2:16
dr. ruan discusses btk inhibitors in mcl
-
1:03
advancements in mcl treatment
-
1:16
dr. patel on differences between btk inhibitors in mcl
-
7:11
selection of a btk inhibitor in relapsed/refractory mcl
-
1:22
dr. kaplan on the combination of ibrutinib and venetoclax in mcl
-
1:09
dr. ritchie on the immunologic impact of long-term venetoclax/ibrutinib in r/r mcl
-
5:07
btk inhibitors in mcl: aes, specificity, and interactions
-
2:00
dr. goy discusses btk inhibitors in mcl
-
1:27
dr. ritchie on immunological response to venetoclax/ibrutinib in r/r mcl
-
0:55
dr. smith on safety profiles of btk inhibitors in mcl
-
1:18
dr. danilov on venetoclax plus btk inhibitors in cll
-
1:03
dr. wang discusses promise of venetoclax in mcl
-
2:38
toby eyre | would venetoclax monotherapy be a good option for r/r mcl post-btk inhibitor therapy?
-
2:40
btk inhibitors for r/r mcl: current uses and insights from the vipor study